The FINANCIAL — Nestle agreed to buy Aimmune Therapeutics Inc. for $2.6 billion, adding a promising peanut allergy treatment to its portfolio of coffee, snacks and water. The Swiss owner of Nespresso will pay $34.50 a share for the U.S. biotech firm, almost triple its last closing price. Aimmune makes a therapy to help reduce allergic reactions to peanuts in children and teens by exposing them to tiny doses over time. FDA approved Aimmune Therapeutics’ Palforzia which makes it the first medication approved for food allergies in teens and children. Nestlé and Aimmune Therapeutics, Inc. a biopharmaceutical company developing and commercializing…
Read More »
